Clinical Trial Update: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating AI plus everolimus in postmenopausal women with ER+/HER2-, low risk breast cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AI (aromatase inhibitor)
• Everolimus (everolimus)

Snippet

Sponsor: Yale University | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-02-01